Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Slides:

Advertisements

Similar presentations

Praxbind® - Idarucizumab

Advertisements

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.

Recognition and First-Line Treatment of Anaphylaxis

Ambulatory Blood Pressure Monitoring in Clinical Practice: A Review

Warfarin Toxicity Treatment & Management

Bleeding Toes in Diabetic Neuropathy

Joanne van Ryn, PhD, Lawrence Baruch, MD, Andreas Clemens, MD

Bruised Black and Blue: Acquired Hypoprothrombinemia

How Well Are Pulses Measured

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

Bleeding Toes in Diabetic Neuropathy

Suggested approach to patients with dabigatran-associated bleeding

James H. Liu, MD The American Journal of Medicine

Bruised Black and Blue: Acquired Hypoprothrombinemia

Understanding EMPA-REG OUTCOME

Kenneth Todd Moore, MS, Dino Kröll, MD

Pure red cell aplasia following pegylated interferon α treatment

Truman J. Milling, MD, Scott Kaatz, DO, MSc

Athena Philis-Tsimikas, MD The American Journal of Medicine

George Dailey, MD Mayo Clinic Proceedings

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Menno V. Huisman, MD, PhD, John Fanikos, RPh, MBA

Epidemiology of Myelodysplastic Syndromes

Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus C. Thorborg,

The Impact of the Host on Fungal Infections

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Seasonal variations and age-related changes in human sperm count, motility, motion parameters, morphology, and white blood cell concentration Grace M.

Michael A. Pfaller, MD The American Journal of Medicine

Recent advances in mechanical ventilation

Marcel Levi, MD, C. Erik Hack, MD, Marinus H. van Oers, MD

Artificial Hyperparathyroidism—Think Twice Before Taking Your Blood Sample Daniel Foehring, MD, Lars Moeller, MD, Dagmar Fuhrer, MD, Harald Lahner, MD

The Reply The American Journal of Medicine

Type III hyperlipoproteinemia unmasked by HIV anti-retroviral therapy

Reversal of Overanticoagulation in Very Elderly Hospitalized Patients with an INR above 5.0: 24-Hour INR Response after Vitamin K Administration Eric.

Invasive Mycoses: Strategies for Effective Management

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

TIA for the Internist The American Journal of Medicine

Genitourinary symptoms in the menopausal transition

James E. Novak, Khalid Alamiri, Jerry Yee

Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding Joanna M. Peloquin, MD, Siamak M. Seraj, MD,

Understanding EMPA-REG OUTCOME

Gout in African Americans

Patricia K. Stinchfield, RN, MS, CPNP The American Journal of Medicine

Treatment of hepatitis C

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Bromide Toxicity from Consumption of Dead Sea Salt

The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study Mohamed G. Atta, MD, MPH, Kesha Baptiste-Roberts,

Repeated Hemoglobin A1C Ordering in the VA Health System

Toxic Effects Associated With Consumption of Zinc

Pulmonary Langerhans' Cell Histiocytosis

Insomnia in the Elderly: Cause, Approach, and Treatment

To Reduce Stroke with PFO Closure, Respect the Shunt

Massive Aquaresis After Tolvaptan Administration and Albumin Infusion in a Patient with Alcoholic Cirrhosis Charles Cho, MD, Joy L. Logan, MD, Yeong-Hau.

Purple Urinary Bag Syndrome

National Trends in Ambulatory Oral Anticoagulant Use

Plasma Lactescence in Acute Pancreatitis

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model G. Dickneite, I. Pragst British.

Falls in Older Adults: Risk Assessment, Management and Prevention

Invasive Mycoses: Diagnostic Challenges

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

Matthew W. Martinez, MD, Keith G. Rasmussen, MD, Paul S

Toward a More Responsible News Media

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Frédéric Michard, MD, PhD, Apurva Badheka, MD

Mean nasopharyngeal pressure during high-flow oxygen therapy, with mouth open or closed. Mean nasopharyngeal pressure during high-flow oxygen therapy,

Presentation transcript:

Evidence Supporting Idarucizumab for the Reversal of Dabigatran Charles V. Pollack, MA, MD The American Journal of Medicine Volume 129, Issue 11, Pages S73-S79 (November 2016) DOI: 10.1016/j.amjmed.2016.06.008 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Time course of the dilute thrombin time and ecarin clotting time before and after the administration of idarucizumab. Reprinted with permission of Massachusetts Medical Society from Pollack et al.25 The analyses included 51 patients who had serious bleeding (group A; A and C) and 39 who required urgent surgery or intervention (group B; B and D). Idarucizumab was administered in 2 infusions. Blood samples were obtained at baseline, after the first infusion, at 10-30 minutes after the administration of the second infusion, and at 1, 2, 4, 12, and 24 hours. Data are presented as box-and-whisker plots, in which the top and bottom of the rectangles indicate the 75th and 25th percentiles, respectively; the horizontal lines within the rectangles indicate the 50th percentile; the lines above and below the rectangles indicate the 90th and 10th percentiles, respectively; and the dots above and below the lines indicate the 95th and 5th percentiles, respectively. The dashed lines indicate the upper limit of the normal range for the tests. The American Journal of Medicine 2016 129, S73-S79DOI: (10.1016/j.amjmed.2016.06.008) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Management of bleeding in patients taking direct oral anticoagulants (DOACs). Possible therapeutic measures in case of minor or severe bleeding in patients on DOAC therapy. Based on van Ryn et al.8 Adapted with permission of Oxford University Press from Heidbuchel et al.5 aPCC = activated prothrombin complex concentrate; IV = intravenous; NOAC = novel oral anticoagulant; PCC = prothrombin complex concentrate; RBC = red blood cell count; WBC = white blood cell count. The American Journal of Medicine 2016 129, S73-S79DOI: (10.1016/j.amjmed.2016.06.008) Copyright © 2016 Elsevier Inc. Terms and Conditions